title: Risks and benefits of thrombolysis in the elderly.
abstract: OBJECTIVE
  Stroke incidence continues to rise exponentially with age even as temporal trends in some population risk factors increase and others decline. In general, older patients with stroke have worse outcomes compared to their younger counterparts. Stroke severity, concurrent medical problems, prestroke disability, and less-aggressive acute and chronic management are a few contributing factors to account for this poor prognosis. Acute thrombolysis therapy is the only proven treatment in acute ischemic stroke. However, elderly patients have mostly been excluded from acute revascularization studies, due predominantly to their overall poor prognosis and the fear of hemorrhagic complications from these treatments. Despite this, there is no evidence to suggest that the risk benefit ratio of thrombolysis treatment is substantially different in the elderly than in younger ischemic stroke patients.
  
  
  RESULTS
  In this review, we briefly examine the stroke risk factor profile and outcome in the elderly and review the current evidence regarding intravenous and intra-arterial revascularization treatments.
  
  
  CONCLUSIONS
  We feel that carefully selected patients who meet eligibility criteria for thrombolysis should not be denied this therapy on the basis of age alone.
authors.affiliation: Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
authors.forename: Negar
authors.initials: N
authors.lastname: Asdaghi
authors.forename: Kenneth S
authors.initials: KS
authors.lastname: Butcher
authors.forename: Michael D
authors.initials: MD
authors.lastname: Hill
mesh_terms: D000367:Age Factors; D000368:Aged / Q000502:physiology*; D002543:Cerebral Hemorrhage / Q000473:pathology / Q000517:prevention & control; D057510:Endovascular Procedures; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D012307:Risk Factors; D013300:Streptokinase / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014652:Vascular Diseases / Q000150:complications / Q000188:drug therapy
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator